Bristol Myers Squibb (BMS) has agreed to pay US$650 M upfront to access Eisai’s anti-folate receptor alpha (FRalpha) antibody, MORAb-202, which is currently in a Phase I clinical study in Japan and Phase I/II trials in the US. In preclinical studies, MORAb-202 showed promise in combination with farletuzumab, a humanized monoclonal antibody of IgG1/kappa, suggesting that the drug exhibits the antitumour activity on the FRA-negative cancer cells surrounding the FRA-positive cancer cells. With the deal, which is worth up to US$3.1 B, BMS will gain commercialisation rights of MORAb-202 in US and Canada, while Eisai will retain rights in Japan, China, countries in the Asia-Pacific region, Europe, and Russia.